When was Fizimed founded?

Fizimed was founded in 2017 and raised its 1st funding round 8 years after it was founded.

Where is Fizimed located?

Fizimed is headquartered in Strasbourg, France.

Who is the current CEO of Fizimed?

Emeline Hahn of Fizimed. They have also founded 1 company.

How many employees does Fizimed have?

As of Jun 30, 2026, the latest employee count at Fizimed is 27.

Is Fizimed a funded company?

Fizimed is a funded company, having raised a total of €***** in its 1st and only funding round, a Series A round on Mar 13, 2025.

When was the latest funding round of Fizimed?

Fizimed's latest funding was a €***** Series A round on Mar 13, 2025, with participation from 3 investors.

Where does Fizimed rank among its competitors?

Fizimed ranks 5th amongst 116 active competitors, of which 33 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was UroMems, which secured $60M in May, 2026.

Who are the top competitors of Fizimed?

Fizimed's top competitors include Axonics, Amber Therapeutics and Valencia Technologies. Among them, UroMems secured the most recent funding round in May, 2026.

Fizimed - 2026 Company Profile, Team, Funding & Competitors

Company Details

Fizimed manufactures a device for controlling urinary leakage. The product Emy is the wireless probe connected to a mobile application. It allows users to do the rehabilitation at home alone. The Emy biofeedback device is used in addition to the perineum reeducation sessions carried out by practitioners and allows patients to continue their exercises at home and practitioners track their work progress.

Website: emy.fizimed.com
Social

Key Metrics

Founded Year

2017

Location

Strasbourg, France

Stage

Series A

Total Funding

$4.35M in 1 round

Latest Funding Round

Series A, Mar 13, 2025, €*****

Investors

Bpifrance & 3 more

Ranked

5^th among 116 active competitors

Employee Count

27 as on Jun 30, 2026

Similar Companies

Laborie Medical & 49 more

View Fizimed's full profile

Fizimed is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Fizimed CIN: 829447853 , France, Active	Jun 01, 2017	-	-	-

Fizimed has raised a total funding of $4.35M over 1 round. Its latest funding round was a Series A round on Mar 13, 2025 for €*****. 3 investors participated in its latest round. Fizimed has 4 institutional investors.

Here is the list of recent funding rounds of Fizimed:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 13, 2025	1169387	Series A	5504883	7364673	9305004	8882395

Access funding benchmarks and valuations. Sign up today!

View details of Fizimed's funding rounds and investors

The founders of Fizimed are Emeline Hahn, Allan Mabilais and Paul Grandemange. Emeline Hahn is the CEO of Fizimed.

Here are the details of Fizimed's key team members:

Emeline Hahn: Co-Founder & CEO of Fizimed.
Contact Info: 2 email addresses
Allan Mabilais: Co-Founder & CTO of Fizimed.
Contact Info: 1 email address
Paul Grandemange: Co-Founder of Fizimed.
Contact Info: 1 email address

View details of Fizimed's Founder profiles and Board Members

Fizimed's employee count trend

Fizimed has 27 employees as of Jun 26. Here is Fizimed's employee count trend over the years:

Uncover Fizimed's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Fizimed include Axonics, Amber Therapeutics and Valencia Technologies. Here is the list of Top 10 competitors of Fizimed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Axonics 2013, Irvine (United States), Acquired	Developer of a device to control urinary and bowel movement	$143M	Advent Life Sciences, Edmond de Rothschild ... & 9 others	66/100
2nd	Amber Therapeutics 2021, London (United Kingdom), Series A	Developer of bioelectrical therapies for functional disorders of the peripheral nervous system	$100M	New Enterprise Associates, F-Prime Capital ... & 5 others	59/100
3rd	Valencia Technologies 2011, Santa Clarita (United States), Acquired	Developer of a coin-sized pacemaker-like device for the treatment of hypertension	$56.9M	BMG, Lifeblood Capital & 1 others	59/100
4th	UroMems 2011, Grenoble (France), Series D	Developer of active implantable devices for urological incontinence	$150M	Financiere Arbevel, Wellington Partners Venture Capital ... & 16 others	59/100
5th	Fizimed 2017, Strasbourg (France), Series A	Manufacturer of device for controlling urinary leakage	$4.35M	Bpifrance, UNIQA Group & 2 others	58/100
6th	Laborie Medical 1967, Mississauga (Canada), Acquired	Provider of products for lower urinary tract dysfunctions in females	-	Investor, Audax Private Equity	57/100
7th	COSM 2017, Toronto (Canada), Seed	Provider of devices for women pelvic floor disorder	$5.65M	iGan Partners, Fusion Fund & 9 others	56/100
8th	Affluent Medical 2011, Paris (France), Public	Developer of minimally invasive prostheses for structural heart disease, vascular therapy, and urology	$11.7M	Truffle Capital, Hayk Holding & 8 others	55/100
9th	Levee Medical 2021, Durham (United States), Series B	Developer of urological devices for post-prostatectomy	$36.2M	-	52/100
10th	Devicare 2012, Barcelona (Spain), Series A	Developer of home solutions for diagnosis, prognosis, treatment and monitoring of chronic diseases	$7.13M	Advanced MedTech, Caixa Capital Risc & 8 others	50/100